PTIX (protagenic.com) Future Price to Earnings
The forward P/E ratio history of Protagenic Therapeutics (PTIX) demonstrates an evolution from strict adherence to laboratory chemical disposal standards to current valuations. The 0.00 metric confirms the level of interest in synthetic peptides for depression, which is creating demand inertia. Meanwhile, the lack of stable cash flows due to clinical trials of neuropeptides for anxiety maintains high volatility for the asset.
PTIX (Protagenic): analytical breakdowns and indicator data
- stock value and consensus price forecast:
- business market valuation indicators:
- balance sheet equity data:
- debt level and financial liquidity data:
Total Debt to Capital Protagenic Therapeutics|PTIX - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Protagenic Therapeutics|PTIX - Company Cumulative Debt|Debt to Book Capitalization Ratio Protagenic Therapeutics Inc.|PTIX - Company Long-Term Indebtedness|Company Short-Term Debts Protagenic Therapeutics|Quick Ratio protagenic.com
- financial results and valuation multiples details:
PTIX - Net Income|Future Profit Protagenic Therapeutics|PTIX - Company Value to Net Income|Projected Price to Earnings Protagenic Therapeutics|PTIX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Protagenic Therapeutics Inc.|PTIX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Protagenic Therapeutics|PTIX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months protagenic.com|PTIX - Earnings per share increase in current year|Earnings growth forecast for next year Protagenic Therapeutics
Analysis of all company metrics:PTIX Protagenic Therapeutics, Inc.
Forward P/E determines business value through the ratio of current market capitalization to expected net income, allowing investors to identify asset overvaluation and avoid buying at peaks. When analyzing the consensus P/E forecast for Protagenic Therapeutics (PTIX), one must consider the impact of Protagenic Therapeutics expenditures on energy efficiency and laboratory filtration, as environmental costs directly adjust future profitability and the final multiple.
Who Protagenic Therapeutics competes with
Future Price to Earnings Biogen (BIIB)|NBIX (Neurocrine) - Future Price to Earnings Multiple|Future Price to Earnings Regencell RGC|Axsome Corp (AXSM) - Projected Price to Earnings Ratio|ACAD: Projected Price to Earnings|xenon-pharma.com - Market Cap to Future Earnings Ratio|VKTX: Forward P/E Multiple|Supernus Pharmaceuticals, Inc. (SUPN) - Forward P/E Multiple|CPRX (Catalyst Pharmaceuticals Inc) - Forward P/E Multiple|DNLI - Forward Price to Earnings Multiple|Forward P/E Multiple HRMY|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Price to Future Earnings Ratio|Praxis Medicines - Forward P/E Multiple|Market Cap to Projected Earnings Anavex Life Sciences Corp AVXL|CBLL: Forward P/E Multiple|Projected Price to Earnings Prothena|Projected Price to Earnings ALEC|ANNX: Future Price to Earnings Multiple|Projected Price to Earnings OMER (Omeros Corporation)|Market Cap to Future Earnings Ratio NGNE|Forward P/E Multiple ACIU (AC Immune)|Future Price to Earnings Multiple VYGR|Neumora Therapeutics, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Scilex Holding|Tevogen Bio Holdings, Inc. (TVGN) - Future Price to Earnings|Alpha Cognition Inc. - Future Price to Earnings Multiple|CGTX (Cognition Therapeutics) - Forward P/E Multiple|Forward P/E Multiple inhibikase.com|Future Price to Earnings Cassava Sciences (SAVA)|ASRT: Price to Expected Earnings Ratio|Forward P/E Multiple COYA (Coya Therapeutics)|VistaGen Therapeutics, Inc. (VTGN) - Projected Price to Earnings Ratio|OVID: Projected Price to Earnings|ABOS - Forward P/E Multiple|CRVO (CervoMed) - Projected Price to Earnings|ATHE: Market Cap to Future Earnings Ratio|CLNN (Clene Inc) - Forward P/E Multiple|PepGen Corp (PEPG) - Market Cap to Projected Earnings|Forward P/E Multiple JUNS|Projected Price to Earnings relmada.com RLMD|Future Price to Earnings Annovis Bio ANVS|Market Cap to Projected Earnings Grace Therapeutics Inc (GRCE)|AIFF - Future Price to Earnings|Price to Expected Earnings Ratio KLTO|NRSN (neurosense-tx.com) - Projected Price to Earnings|RVPH: Market Cap to Future Earnings Ratio|MTVA (MetaVia Inc.) - Forward P/E Multiple|NeurAxis Inc. (NRXS) - Market Cap to Projected Earnings|Projected Price to Earnings HSDT (Helius Medical)|passagebio.com - Price to Future Earnings Ratio|Future Price to Earnings Neuphoria Therapeutics NEUP|NERV: Price to Future Earnings Ratio|Athira Pharma - Forward P/E Multiple|Projected Price to Earnings Ratio Addex Therapeutics Ltd.|ALZN (alzamend.com) - Projected Price to Earnings|Cyclerion Therapeutics, Inc. (CYCN) - Forward P/E Multiple|Future Price to Earnings Pasithea Therapeutics Corp|CRGT: Future Price to Earnings Multiple|Future Price to Earnings Avenue Therapeutics, Inc. (ATXI)|BCLI - Projected Price to Earnings Ratio|Future Price to Earnings Cara Therapeutics, Inc CARA|CHRO (Chromocell) - Price to Expected Earnings Ratio|ELYM - Future Price to Earnings|Future Price to Earnings Multiple ITCI (Intra-Cellular Therapies)|Longboard Pharmaceuticals, Inc. (LBPH) - Future Price to Earnings|Projected Price to Earnings Ratio Marinus Pharmaceuticals Inc (MRNS)|Projected Price to Earnings NKGN|NRBO (NeuroBo Pharma) - Market Cap to Future Earnings Ratio|Forward P/E Multiple SAGE|Forward P/E Multiple synaptogen.com (SNPX)|Forward P/E Multiple TRVN (Trevena)|Forward Price to Earnings Multiple Vigil Neuroscience Inc.|Anew Medical - Forward P/E Multiple|Projected Price to Earnings Ratio Cerevel Corp
